演題詳細

ポスター / Poster

ポスター 23 (Poster 23) :低悪性度B細胞リンパ腫:ベンダムスチン

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
瀧本 理修 (Rishu Takimoto):1
1:札幌医科大学医学部附属病院 腫瘍・血液内科
 
前へ戻る

Effect and safety of bendamustine for indolent and mantle cell lymphoma in a single institution

演題番号 : PS-1-169

木村 裕和 (Hirokazu Kimura):1、羽山 慧似 (Kei Hayama):1、赤川 直之 (Naoyuki Akagawa):1、杉本 恵菜 (Ena Sugimoto):1、花崎 俊輔 (Shunsuke Hanasaki):1、木村 明華 (Sayaka Kimura):1、西岡 和昭 (Kazuaki Nishioka):1、翁 祖誠 (Sosei Okina):1、鎌田 浩稔 (Hirotoshi Kamata):1、栂野 富輝 (Tomiteru Togano):1、宮崎 浩二 (Koji Miyazaki):1、檀原 幹生 (Mikio Danbara):1、堀江 良一 (Ryouichi Horie):1、東原 正明 (Masaaki Higashihara):1

1:Department of Hematology, Kitasato University School of Medicine, Japan

 

[Introduction]We retrospectively reviewed medical records relapsed refractory indolent and mantle cell lymphoma patients who received bendamustine therapy at our hospital to evaluate efficacy and adverse events. [Objectives]Eleven patiens of relapsed refractory indolent and mantle cell lymphoma were 5 male and 10 female with median age of 69 y.o(range 57-83). Median duration of disease was 61 months(21-103). Various pretreatments were done : R-CHOP 11, CPA 3, Rituximab 2, Radiation 2, R-cycloBEAP 1, R-flu 1, R-ACES 1, R-ESHAP 1 and R-CMD 1. [Methods]Patients received bendamustine 90 or 120 mg/m^2 on days 1 and 2 of each 21 day cycle with / without rituximab 375 mg/m^2 on days 0. [Results]Eleven patients (4 with mantle cell lymphoma, 7 with indolent non hodgkin lymphoma) were enrolled and treated. One patient received only bendamustine 120 mg/m^2, 6 patients bendamustine 120 mg/m^2 with rituximab and 4 patients bendamustine 90 mg/m^2 with rituximab. Median follow-up was 10.3 months(3.2-20). Of the 11 patients evaluable for treatment response, 63.6% achieved a partial response or complete response. Two patients maintained stable disease at the posttreatment restaging. The overall response rate (proportion of patients achieving a CR or PR) was 57.1% in follicular lymphoma and 75% in mantle cell lymphoma. One-year OS is 90.9 %(95% confidence interval[CI], 85-97%). One-year EFS is 77.9 %(95% [CI], 73-82%). Grade 3/4 adverse events included neutropenia, thrombocytopenia, and anemia. [Conclusion]As for bendamustine, the effect was admitted for indolent and mantle cell lymphoma.

前へ戻る